Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.

Hong J, Han SW, Ham HS, Kim TY, Choi IS, Kim BS, Oh DY, Im SA, Kang GH, Bang YJ, Kim TY.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1323-31. doi: 10.1007/s00280-010-1425-7. Epub 2010 Aug 24.

PMID:
20734048
2.

Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer.

Li J, Yin J, Zhu X, Liu Y, Cao J, Lu F, Zuo Y.

Anticancer Drugs. 2008 Aug;19(7):745-8. doi: 10.1097/CAD.0b013e3283067694.

PMID:
18594218
3.

A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer.

Kato K, Inaba Y, Tsuji Y, Esaki T, Yoshioka A, Mizunuma N, Mizuno T, Kusaba H, Fujii H, Muro K, Shimada Y, Shirao K.

Jpn J Clin Oncol. 2011 Jan;41(1):63-8. doi: 10.1093/jjco/hyq158. Epub 2010 Sep 6.

PMID:
20819832
4.

Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer.

Zang DY, Lee BH, Park HC, Song HH, Kim HJ, Jung JY, Kim JH, Kim HY, Kwon JH, Hwang SW, Park SR, Park CH, Kim KO, Kim MJ, Jang KM.

Ann Oncol. 2009 May;20(5):892-6. doi: 10.1093/annonc/mdn721. Epub 2009 Jan 19.

PMID:
19153122
5.

The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.

Liang J, Jiang T, Yao RY, Liu ZM, Lv HY, Qi WW.

Cancer Chemother Pharmacol. 2010 Aug;66(3):493-500. doi: 10.1007/s00280-009-1186-3. Epub 2009 Dec 4.

PMID:
19960344
6.

Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer.

Park I, Lee JL, Ryu MH, Chang HM, Kim TW, Sym SJ, Lee SS, Jang G, Yoo C, Bae KS, Kang YK.

Cancer Chemother Pharmacol. 2010 Feb;65(3):473-80. doi: 10.1007/s00280-009-1052-3. Epub 2009 Jun 24.

PMID:
19551382
7.

Clinical study of tegafur-gimeracil-oteracil potassium capsule (s-1) and oxaliplatin combination chemotherapy in advanced colorectal cancer.

Liu H, Wang Y, Li G, Song W, Wang R.

J Cancer Res Ther. 2015 Apr-Jun;11(2):331-5. doi: 10.4103/0973-1482.157339.

8.

The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.

Nakamura M, Yamada Y, Muro K, Takahashi K, Baba H, Sasaki Y, Komatsu Y, Satoh T, Mishima H, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K.

Future Oncol. 2015;11(10):1471-8. doi: 10.2217/fon.15.59.

9.

S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.

Kim SY, S Hong Y, K Shim E, Kong SY, Shin A, Baek JY, Jung KH.

Br J Cancer. 2013 Sep 17;109(6):1420-7. doi: 10.1038/bjc.2013.479. Epub 2013 Aug 20.

10.

Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer.

Sørbye H, Glimelius B, Berglund A, Fokstuen T, Tveit KM, Braendengen M, Øgreid D, Dahl O.

J Clin Oncol. 2004 Jan 1;22(1):31-8.

PMID:
14701765
11.

Retrospective study of S-1 versus tegafur/uracil and oral leucovorin in patients with metastatic colorectal cancer.

Shibahara K, Yamamoto M, Kakeji Y, Sakata H, Maehara Y.

Anticancer Res. 2008 May-Jun;28(3B):1779-83.

12.

Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer.

Kim JY, Do YR, Park KU, Kim JG, Chae YS, Kim MK, Lee KH, Ryoo HM, Bae SH, Baek JH, Song HS.

Cancer Chemother Pharmacol. 2011 Mar;67(3):527-32. doi: 10.1007/s00280-010-1353-6. Epub 2010 May 12.

PMID:
20461377
13.

Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer.

Wang ZQ, Zhang DS, Xu N, Luo DY, Deng YH, Wang FH, Luo HY, Qiu MZ, Li YH, Xu RH.

Chin J Cancer. 2016 Jan 6;35:8. doi: 10.1186/s40880-015-0061-3.

14.

An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.

Caponigro F, Lacombe D, Twelves C, Bauer J, Govaerts AS, Marréaud S, Milano A, Anthoney A.

Eur J Cancer. 2009 Jan;45(1):48-55. doi: 10.1016/j.ejca.2008.08.011. Epub 2008 Sep 20.

PMID:
18809314
15.

Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.

Taïeb J, Artru P, Paye F, Louvet C, Perez N, André T, Gayet B, Hebbar M, Goebel FM, Tournigand C, Parc R, de Gramont A.

J Clin Oncol. 2005 Jan 20;23(3):502-9.

PMID:
15659495
16.

Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model.

Doi Y, Okada T, Matsumoto H, Ichihara M, Ishida T, Kiwada H.

Cancer Sci. 2010 Nov;101(11):2470-5. doi: 10.1111/j.1349-7006.2010.01678.x.

17.

Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.

Hochster H, Chachoua A, Speyer J, Escalon J, Zeleniuch-Jacquotte A, Muggia F.

J Clin Oncol. 2003 Jul 15;21(14):2703-7.

PMID:
12860947
18.

Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.

Chu QS, Hammond LA, Schwartz G, Ochoa L, Rha SY, Denis L, Molpus K, Roedig B, Letrent SP, Damle B, DeCillis AP, Rowinsky EK.

Clin Cancer Res. 2004 Aug 1;10(15):4913-21.

19.

Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety.

Tanioka H, Honda M, Tanaka C, Morita Y, Ishibashi K, Kato T, Matsuda C, Kataoka M, Satake H, Munemoto Y, Kobayashi K, Takahashi M, Nakata K, Sakamoto J, Oba K, Mishima H.

Int J Clin Oncol. 2019 Jul;24(7):836-841. doi: 10.1007/s10147-019-01414-0. Epub 2019 Feb 18.

PMID:
30778794
20.

Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.

Tomoda M, Kawahara H, Watanabe K, Enomoto H, Akiba T, Yanaga K.

Anticancer Res. 2014 Jan;34(1):191-4.

PMID:
24403461

Supplemental Content

Support Center